Literature DB >> 32150344

Somatic Liver Knockout (SLiK): A Quick and Efficient Way to Generate Liver-Specific Knockout Mice Using Multiplex CRISPR/Cas9 Gene Editing.

Collin G Johnson1,2, Tong Chen3,4, Nika Furey2,4, Madeline G Hemmingsen1,4, Karl-Dimiter Bissig1,2,3,4,5.   

Abstract

Somatic liver knockout (SLiK) is a method developed to rapidly generate a liver-specific knockout of one or several genes. This technique combines the strengths of CRISPR/Cas9 gene editing and hydrodynamic tail-vein injection, a simple in vivo method for transfection of hepatocytes, to harness the powerful selection pressure of tyrosinemic livers to replace host hepatocytes with any desired gene deletion. In this protocol, we will describe sgRNA design and cloning, hydrodynamic tail-vein injection of targeting constructs, and screening and validation methods for efficient in vivo gene editing.
© 2020 by John Wiley & Sons, Inc. Support Protocol 1: sgRNA design Support Protocol 2: sgRNA construction: daisy chaining multiple sgRNAs Basic Protocol: Delivery of DNA by hydrodynamic tail-vein injection and liver repopulation of edited hepatocytes Support Protocol 3: Validation of CRISPR/Cas9 cutting in vivo. © 2020 John Wiley & Sons, Inc.

Entities:  

Keywords:  CRISPR; animal model; genome engineering; somatic liver knockout

Mesh:

Substances:

Year:  2020        PMID: 32150344      PMCID: PMC7500866          DOI: 10.1002/cpmb.117

Source DB:  PubMed          Journal:  Curr Protoc Mol Biol        ISSN: 1934-3647


  18 in total

1.  Hydrodynamic liver gene transfer mechanism involves transient sinusoidal blood stasis and massive hepatocyte endocytic vesicles.

Authors:  A Crespo; A Peydró; F Dasí; M Benet; J J Calvete; F Revert; S F Aliño
Journal:  Gene Ther       Date:  2005-06       Impact factor: 5.250

2.  Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA.

Authors:  F Liu; Y Song; D Liu
Journal:  Gene Ther       Date:  1999-07       Impact factor: 5.250

Review 3.  Genetic control of morphogenetic and biochemical differentiation: lethal albino deletions in the mouse.

Authors:  S Gluecksohn-Waelsch
Journal:  Cell       Date:  1979-02       Impact factor: 41.582

4.  Characterization of genomic deletion efficiency mediated by clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells.

Authors:  Matthew C Canver; Daniel E Bauer; Abhishek Dass; Yvette Y Yien; Jacky Chung; Takeshi Masuda; Takahiro Maeda; Barry H Paw; Stuart H Orkin
Journal:  J Biol Chem       Date:  2014-06-06       Impact factor: 5.157

5.  Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses.

Authors:  Dan Wang; Haiwei Mou; Shaoyong Li; Yingxiang Li; Soren Hough; Karen Tran; Jia Li; Hao Yin; Daniel G Anderson; Erik J Sontheimer; Zhiping Weng; Guangping Gao; Wen Xue
Journal:  Hum Gene Ther       Date:  2015-07       Impact factor: 5.695

6.  Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I.

Authors:  M Grompe; S Lindstedt; M al-Dhalimy; N G Kennaway; J Papaconstantinou; C A Torres-Ramos; C N Ou; M Finegold
Journal:  Nat Genet       Date:  1995-08       Impact factor: 38.330

7.  Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model.

Authors:  Karl-Dimiter Bissig; Tam T Le; Niels-Bjarne Woods; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-11       Impact factor: 11.205

8.  CRISPR-mediated direct mutation of cancer genes in the mouse liver.

Authors:  Wen Xue; Sidi Chen; Hao Yin; Tuomas Tammela; Thales Papagiannakopoulos; Nikhil S Joshi; Wenxin Cai; Gillian Yang; Roderick Bronson; Denise G Crowley; Feng Zhang; Daniel G Anderson; Phillip A Sharp; Tyler Jacks
Journal:  Nature       Date:  2014-08-06       Impact factor: 49.962

9.  Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease.

Authors:  Kelsey E Jarrett; Ciaran M Lee; Yi-Hsien Yeh; Rachel H Hsu; Rajat Gupta; Min Zhang; Perla J Rodriguez; Chang Seok Lee; Baiba K Gillard; Karl-Dimiter Bissig; Henry J Pownall; James F Martin; Gang Bao; William R Lagor
Journal:  Sci Rep       Date:  2017-03-16       Impact factor: 4.379

10.  Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia.

Authors:  Francis P Pankowicz; Mercedes Barzi; Xavier Legras; Leroy Hubert; Tian Mi; Julie A Tomolonis; Milan Ravishankar; Qin Sun; Diane Yang; Malgorzata Borowiak; Pavel Sumazin; Sarah H Elsea; Beatrice Bissig-Choisat; Karl-Dimiter Bissig
Journal:  Nat Commun       Date:  2016-08-30       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.